These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 7606966)

  • 1. New prognostic factors in lung cancer. Biologic prophets of cancer cell aggression.
    Mountain CF
    Chest; 1995 Jul; 108(1):246-54. PubMed ID: 7606966
    [No Abstract]   [Full Text] [Related]  

  • 2. Biologic and molecular prognostic factors--impact on treatment of patients with non-small cell lung cancer.
    Johnson BE
    Chest; 1995 Jun; 107(6 Suppl):287S-290S. PubMed ID: 7781407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multigene mutation analysis on cytologic samples.
    Fleury-Feith J; Gounant V; Lacave R; Cadranel J; Bernaudin JF
    Chest; 2011 Dec; 140(6):1664. PubMed ID: 22147827
    [No Abstract]   [Full Text] [Related]  

  • 4. Non-small cell lung cancer: clinical value of new biological predictors.
    Graziano SL
    Lung Cancer; 1997 Jun; 17 Suppl 1():S37-58. PubMed ID: 9213302
    [No Abstract]   [Full Text] [Related]  

  • 5. Prognostic molecular markers in non-small cell lung cancer.
    Nikliński J; Niklińska W; Laudanski J; Chyczewska E; Chyczewski L
    Lung Cancer; 2001 Dec; 34 Suppl 2():S53-8. PubMed ID: 11720742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel molecular staging protocol for non-small cell lung cancer.
    Miyake M; Adachi M; Huang C; Higashiyama M; Kodama K; Taki T
    Oncogene; 1999 Apr; 18(14):2397-404. PubMed ID: 10327061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do molecular markers predict survival in non-small-cell lung cancer?
    Greatens TM; Niehans GA; Rubins JB; Jessurun J; Kratzke RA; Maddaus MA; Niewoehner DE
    Am J Respir Crit Care Med; 1998 Apr; 157(4 Pt 1):1093-7. PubMed ID: 9563724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA alterations at proto-oncogene loci and their clinical significance in operable non-small cell lung cancer.
    Hajj C; Akoum R; Bradley E; Paquin F; Ayoub J
    Cancer; 1990 Aug; 66(4):733-9. PubMed ID: 2167142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multigene mutation analysis of metastatic lymph nodes in non-small cell lung cancer diagnosed by endobronchial ultrasound-guided transbronchial needle aspiration.
    Nakajima T; Yasufuku K; Nakagawara A; Kimura H; Yoshino I
    Chest; 2011 Nov; 140(5):1319-1324. PubMed ID: 21527506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.
    Mitsudomi T; Steinberg SM; Nau MM; Carbone D; D'Amico D; Bodner S; Oie HK; Linnoila RI; Mulshine JL; Minna JD
    Oncogene; 1992 Jan; 7(1):171-80. PubMed ID: 1311061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New prognostic factors in resectable non-small cell lung cancer.
    Smit EF; Groen HJ; Splinter TA; Ebels T; Postmus PE
    Thorax; 1996 Jun; 51(6):638-46. PubMed ID: 8693450
    [No Abstract]   [Full Text] [Related]  

  • 12. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy.
    Schiller JH; Adak S; Feins RH; Keller SM; Fry WA; Livingston RB; Hammond ME; Wolf B; Sabatini L; Jett J; Kohman L; Johnson DH
    J Clin Oncol; 2001 Jan; 19(2):448-57. PubMed ID: 11208838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic model of stage II non-small cell lung cancer by a discriminant analysis of the immunohistochemical protein expression.
    Kohri T; Sugano M; Kawashima O; Saito R; Sakurai S; Sano T; Nakajima T
    Surg Today; 2006; 36(12):1039-46. PubMed ID: 17123130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Molecular biological diagnosis of non-small-cell carcinoma of the lung and its application to therapy].
    Sugio K; Fukuyama Y; Maruyama R; Saito G; Nishioka K; Mitsutomi T; Sugimachi K
    Nihon Kyobu Geka Gakkai Zasshi; 1997 Mar; 45(3):403-5. PubMed ID: 9235359
    [No Abstract]   [Full Text] [Related]  

  • 15. Biological prognostic factors in non-small cell lung cancer.
    Scagliotti GV; Masiero P; Pozzi E
    Lung Cancer; 1995 Apr; 12 Suppl 1():S13-25. PubMed ID: 7551921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High expression of MAGE-A9 in tumor and stromal cells of non-small cell lung cancer was correlated with patient poor survival.
    Zhang S; Zhai X; Wang G; Feng J; Zhu H; Xu L; Mao G; Huang J
    Int J Clin Exp Pathol; 2015; 8(1):541-50. PubMed ID: 25755744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors in NSCLC. Recent experiences.
    van Zandwijk N; Mooi WJ; Rodenhuis S
    Lung Cancer; 1995 Apr; 12 Suppl 1():S27-33. PubMed ID: 7551931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic evolutionary staging of early non-small cell lung cancer: the P53 --> HER-2/NEU --> ras sequence.
    Shackney SE; Smith CA; Pollice A; Levitt M; Magovern JA; Wiechmann RJ; Silverman J; Sweeney L; Landreneau RJ
    J Thorac Cardiovasc Surg; 1999 Aug; 118(2):259-67. PubMed ID: 10424999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular oncogenes and suppressor genes as prognostic markers in cancer.
    Duffy MJ
    Clin Biochem; 1993 Dec; 26(6):439-47. PubMed ID: 8124858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of epidermal growth factor receptor overexpression, K-ras point mutation and c-myc amplification in the carcinogenesis of non-small cell lung cancer.
    Sekine I; Takami S; Guang SG; Yokose T; Kodama T; Nishiwaki Y; Kinoshita M; Matsumoto H; Ogura T; Nagai K
    Oncol Rep; 1998; 5(2):351-4. PubMed ID: 9468555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.